Leukomed Sorbact gains NICE approval

Share this article

Leukomed Sorbact gains NICE approval

9 February 2021

Approved for the prevention of surgical site infections


On the 3 February, the National Institute for Health and Care Excellence (NICE) Medical Technologies Advisory Committee approved the use of Leukomed Sorbact (Essity, UK) for the prevention of surgical site infections. The dressing works by binding bacteria to the dressing itself, which is then removed at dressing change. Approval was given for two indications, post-caesarean section or vascular surgery, for closed wounds where low-to-moderate exudate is expected. Cost modelling suggests a saving of £107 per person after caesarean section and £18 per person after vascular surgery.

The full details of the NICE recommendation can be found at


Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.